MANDALMED, INC.

Company Information

Company Name
MANDALMED, INC.
Address
665 3rd Street
Suite 250
SAN FRANCISCO, CA, 94107-1953
Phone
n/a
URL
http://www.mandalmed.com
DUNS
031636660
Number of Employees
4
Hubzone Owned:
N
Minority Owned:
N
Woman Owned:
Y

Award Totals

PROGRAM/PHASE
AWARD AMOUNT ($)
NUMBER OF AWARDS
SBIR Phase I
$1,973,613.00
9
SBIR Phase II
$749,980.00
1
STTR Phase I
$125,000.00
1
Chart code to be here

Award List

  1. GALECTIN 1 FOR MULTIPLE SCLEROSIS

    Amount: $135,801.00

    N/A

    SBIR Phase I 1999 Department of Health and Human Services
  2. N/A

    Amount: $142,130.00

    N/A

    SBIR Phase I 2000 Department of Health and Human Services
  3. THERAPY OF SPINAL CORD INJURY WITH NEUROTROPHIC FACTORS

    Amount: $125,000.00

    N/A

    STTR Phase I 1999 Department of Health and Human Services
  4. Novel Treatment for Breast Cancer: Truncated Galectin-3

    Amount: $236,893.00

    DESCRIPTION (provided by applicant): Despite the available treatments breast cancer ranks second as the cause of death from cancer in women pri ...

    SBIR Phase I 2001 Department of Health and Human Services
  5. Novel Ex Vivo Gene Therapy for Spinal Cord Injury

    Amount: $749,980.00

    DESCRIPTION (provided by applicant): There are approximately 10,000 traumatic spinal cord injuries in the United States each year. The average age of injury is 31 years. The majority (90%) of individu ...

    SBIR Phase II 2003 Department of Health and Human Services
  6. NOVEL EX VIVO GENE THERAPY FOR SPINAL CORD INJURY

    Amount: $155,695.00

    DESCRIPTION (provided by applicant): The goal of the Phase I research is to develop ex vivo gene therapy that will achieve long-term, localized delivery of human neurotrophin-3 (hNT-3) i ...

    SBIR Phase I 2002 Department of Health and Human Services
  7. NO-donor/SOD-mimetics for diabetic nephropathy

    Amount: $134,000.00

    DESCRIPTION (provided by applicant): Vascular disease is the principal cause of morbidity and mortality in patients with diabetes, leading to nephropathy, retinopathy, neuropathy, and ischemic disease ...

    SBIR Phase I 2005 Department of Health and Human Services
  8. Human Sertoli Cell Model for Study of Male Reproductive Function and Toxicity

    Amount: $255,200.00

    DESCRIPTION (provided by applicant): The overall goal of the Phase I research is to develop a three-dimensional model of the blood-testis barrier (BTB) consisting of primary human Sertoli cells cultur ...

    SBIR Phase I 2007 Department of Health and Human Services
  9. Preclinical Testing of Galectin-3C for Multiple Myeloma

    Amount: $363,936.00

    DESCRIPTION (provided by applicant): The overall goal is development of a novel human protein, Galectin-3C, as a treatment for multiple myeloma (MM) that can be given with other agents to increase the ...

    SBIR Phase I 2008 Department of Health and Human Services
  10. Model of the Human Testis for Reproductive Toxicology

    Amount: $250,000.00

    DESCRIPTION (provided by applicant): More than 87,000 chemicals have been developed and distributed over the past 50 years. The vast majority of these have not been tested for potential toxic effects ...

    SBIR Phase I 2011 Department of Health and Human Services

Agency Micro-sites


SBA logo

Department of Agriculture logo

Department of Commerce logo

Department of Defense logo

Department of Education logo

Department of Energy logo

Department of Health and Human Services logo

Department of Homeland Security logo

Department of Transportation logo

Enviromental Protection Agency logo

National Aeronautics and Space Administration logo

National Science Foundation logo
US Flag An Official Website of the United States Government